|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2001; 37:1775-1780 © 2001 by the American College of Cardiology Foundation |
a Department of Nephrology and Cardiology and Congestive Heart Failure Program, Tel Aviv Medical Center, Weizman 6, Tel Aviv, Israel
Manuscript received October 13, 2000; revised manuscript received February 12, 2001, accepted February 19, 2001.
Reprint requests and correspondence: Dr. D. S. Silverberg, Department of Nephrology, Tel Aviv Medical Center, Weizman 6, Tel Aviv, 64239, Israel
OBJECTIVES
This is a randomized controlled study of anemic patients with severe congestive heart failure (CHF) to assess the effect of correction of the anemia on cardiac and renal function and hospitalization.
BACKGROUND
Although mild anemia occurs frequently in patients with CHF, there is very little information about the effect of correcting it with erythropoietin (EPO) and intravenous iron.
METHODS
Thirty-two patients with moderate to severe CHF (New York Heart Association [NYHA] class III to IV) who had a left ventricular ejection fraction (LVEF) of 
40% despite maximally tolerated doses of CHF medications and whose hemoglobin (Hb) levels were persistently between 10.0 and 11.5 g% were randomized into two groups. Group A (16 patients) received subcutaneous EPO and IV iron to increase the level of Hb to at least 12.5 g%. In Group B (16 patients) the anemia was not treated. The doses of all the CHF medications were maintained at the maximally tolerated levels except for oral and intravenous (IV) furosemide, whose doses were increased or decreased according to the clinical need.
RESULTS
Over a mean of 8.2 ± 2.6 months, four patients in Group B and none in Group A died of CHF-related illnesses. The mean NYHA class improved by 42.1% in A and worsened by 11.4% in B. The LVEF increased by 5.5% in A and decreased by 5.4% in B. The serum creatinine did not change in A and increased by 28.6% in B. The need for oral and IV furosemide decreased by 51.3% and 91.3% respectively in A and increased by 28.5% and 28.0% respectively in B. The number of days spent in hospital compared with the same period of time before entering the study decreased by 79.0% in A and increased by 57.6% in B.
CONCLUSIONS
When anemia in CHF is treated with EPO and IV iron, a marked improvement in cardiac and patient function is seen, associated with less hospitalization and renal impairment and less need for diuretics.
| ||||||||||||||||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  H. F. Groenveld, J. L. Januzzi, K. Damman, J. van Wijngaarden, H. L. Hillege, D. J. van Veldhuisen, and P. van der Meer Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., September 2, 2008; 52(10): 818 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Adlbrecht, S. Kommata, M. Hulsmann, T. Szekeres, C. Bieglmayer, G. Strunk, G. Karanikas, R. Berger, D. Mortl, K. Kletter, et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume Eur. Heart J., August 18, 2008; (2008) ehn359v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Anand Anemia and Chronic Heart Failure: Implications and Treatment Options J. Am. Coll. Cardiol., August 12, 2008; 52(7): 501 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kazory and E. A. Ross Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective Circulation, February 19, 2008; 117(7): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang, W. Tong, A. Jain, G. S. Francis, C. M. Harris, and J. B. Young Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J. Am. Coll. Cardiol., February 5, 2008; 51(5): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Ghali, I. S. Anand, W. T. Abraham, G. C. Fonarow, B. Greenberg, H. Krum, B. M. Massie, S. M. Wasserman, M.-L. Trotman, Y. Sun, et al. Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia Circulation, January 29, 2008; 117(4): 526 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Okonko, A. Grzeslo, T. Witkowski, A. K.J. Mandal, R. M. Slater, M. Roughton, G. Foldes, T. Thum, J. Majda, W. Banasiak, et al. Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency: FERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial J. Am. Coll. Cardiol., January 15, 2008; 51(2): 103 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Joyeux-Faure Cellular Protection by Erythropoietin: New Therapeutic Implications? J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 759 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Toblli, A. Lombrana, P. Duarte, and F. Di Gennaro Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1657 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Francis and A. Kanderian Anemia and Heart Failure: A New Pathway? J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1666 - 1667. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Joss, R. Patel, K. Paterson, K. Simpson, C. Perry, and C. Stirling Anaemia is common and predicts mortality in diabetic nephropathy QJM, October 1, 2007; 100(10): 641 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. van Veldhuisen, K. Dickstein, A. Cohen-Solal, D. J.A. Lok, S. M. Wasserman, N. Baker, D. Rosser, J. G.F. Cleland, and P. Ponikowski Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia Eur. Heart J., September 2, 2007; 28(18): 2208 - 2216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Murphy and K. McDonald Treatment of anaemia in chronic heart failure optimal approach still unclear Eur. Heart J., September 2, 2007; 28(18): 2185 - 2187. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Gregory, M. Halliday, C. Averill, N. Bhala, C. Tselepis, and T. Iqbal Iron deficiency anaemia: further education regarding the British Society of Gastroenterology guidelines is required Gut, September 1, 2007; 56(9): 1319 - 1319. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Husemann, M. Fobker, M. Pohlen, C. Bruch, M. Hausberg, G. Breithardt, and H. Reinecke Impact of haemoglobin concentration and chronic kidney disease in patients with coronary heart disease undergoing percutaneous coronary interventions Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2563 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Asaumi, Y. Kagaya, M. Takeda, N. Yamaguchi, H. Tada, K. Ito, J. Ohta, T. Shiroto, K. Shirato, N. Minegishi, et al. Protective Role of Endogenous Erythropoietin System in Nonhematopoietic Cells Against Pressure Overload-Induced Left Ventricular Dysfunction in Mice Circulation, April 17, 2007; 115(15): 2022 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Komajda Anemia in Chronic Heart Failure: Should We Treat It and How? J. Am. Coll. Cardiol., February 20, 2007; 49(7): 763 - 764. [Full Text] [PDF]
|
|
|
|
|
|
P. Ponikowski, S. D. Anker, J. Szachniewicz, D. Okonko, M. Ledwidge, R. Zymlinski, E. Ryan, S. M. Wasserman, N. Baker, D. Rosser, et al. Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial J. Am. Coll. Cardiol., February 20, 2007; 49(7): 753 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Westenbrink, F. W. Visser, A. A. Voors, T. D.J. Smilde, E. Lipsic, G. Navis, H. L. Hillege, W. H. van Gilst, and D. J. van Veldhuisen Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well Eur. Heart J., January 2, 2007; 28(2): 166 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ng Kam Chuen and R. J MacFadyen Variable aetiologies contributing to the anaemia of systolic heart failure are important to individual patient management Eur. Heart J., January 2, 2007; 28(2): 143 - 145. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dec Anemia in Heart Failure: Time to Rethink Its Etiology and Treatment? J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2490 - 2492. [Full Text] [PDF]
|
|
|
|
|
|
J. N. Nanas, C. Matsouka, D. Karageorgopoulos, A. Leonti, E. Tsolakis, S. G. Drakos, E. P. Tsagalou, G. D. Maroulidis, G. P. Alexopoulos, J. E. Kanakakis, et al. Etiology of Anemia in Patients With Advanced Heart Failure J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2485 - 2489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lipsic, R. G. Schoemaker, P. van der Meer, A. A. Voors, D. J. van Veldhuisen, and W. H. van Gilst Protective Effects of Erythropoietin in Cardiac Ischemia: From Bench to Bedside J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2161 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Jie, M. C. Verhaar, M.-J. M. Cramer, K. van der Putten, C. A. J. M. Gaillard, P. A. Doevendans, H. A. Koomans, J. A. Joles, and B. Braam Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors Am J Physiol Renal Physiol, November 1, 2006; 291(5): F932 - F944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J D Newton and I B Squire Glucose and haemoglobin in the assessment of prognosis after first hospitalisation for heart failure Heart, October 1, 2006; 92(10): 1441 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Bolger, F. R. Bartlett, H. S. Penston, J. O'Leary, N. Pollock, R. Kaprielian, and C. M. Chapman Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1225 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hammerman-Rozenberg, J. M. Jacobs, D. Azoulay, and J. Stessman Aspirin prophylaxis and the prevalence of anaemia Age Ageing, September 1, 2006; 35(5): 514 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, G. Takemura, H. Okada, S. Miyata, R. Maruyama, L. Li, M. Higuchi, S. Minatoguchi, T. Fujiwara, and H. Fujiwara Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure Cardiovasc Res, September 1, 2006; 71(4): 684 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Go, J. Yang, L. M. Ackerson, K. Lepper, S. Robbins, B. M. Massie, and M. G. Shlipak Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study Circulation, June 13, 2006; 113(23): 2713 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-D. Tang and S. D. Katz Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options Circulation, May 23, 2006; 113(20): 2454 - 2461. [Full Text] [PDF]
|
|
|
|
|
|
A. Auerbach and L. Goldman Assessing and Reducing the Cardiac Risk of Noncardiac Surgery Circulation, March 14, 2006; 113(10): 1361 - 1376. [Full Text] [PDF]
|
|
|
|
|
|
E. O'Meara, T. Clayton, M. B. McEntegart, J. J.V. McMurray, C. C. Lang, S. D. Roger, J. B. Young, S. D. Solomon, C. B. Granger, J. Ostergren, et al. Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program Circulation, February 21, 2006; 113(7): 986 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Van der Meer, E Lipsic, R. Henning, K Boddeus, J van der Velden, A. Voors, D. van Veldhuisen, W. van Gilst, R. Schoemaker, J. Leemans, et al. Heart Failure after Myocardial Infarction--Benefit beyond Hemoglobin from Erythropoietin: Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats with Heart Failure after Myocardial Infarction J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3449 - 3454. [Full Text] [PDF]
|
|
|
|
|
|
C. Opasich, M. Cazzola, L. Scelsi, S. De Feo, E. Bosimini, R. Lagioia, O. Febo, R. Ferrari, A. Fucili, R. Moratti, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure Eur. Heart J., November 1, 2005; 26(21): 2232 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Okonko, D. J. Van Veldhuisen, P. A. Poole-Wilson, and S. D. Anker Anaemia of chronic disease in chronic heart failure: the emerging evidence Eur. Heart J., November 1, 2005; 26(21): 2213 - 2214. [Full Text] [PDF]
|
|
|
|
|
|
J. George, E. Goldstein, A. Abashidze, D. Wexler, S. Hamed, H. Shmilovich, V. Deutsch, H. Miller, G. Keren, and A. Roth Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner Cardiovasc Res, November 1, 2005; 68(2): 299 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kosiborod, J. P. Curtis, Y. Wang, G. L. Smith, F. A. Masoudi, J. M. Foody, E. P. Havranek, and H. M. Krumholz Anemia and Outcomes in Patients With Heart Failure: A Study From the National Heart Care Project Arch Intern Med, October 24, 2005; 165(19): 2237 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Clark and J. G.F. Cleland Anemia and Chronic Heart Failure: Are We Asking the Right Questions? Circulation, September 20, 2005; 112(12): 1681 - 1683. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chambellan, E. Chailleux, and T. Similowski Prognostic Value of the Hematocrit in Patients With Severe COPD Receiving Long-term Oxygen Therapy Chest, September 1, 2005; 128(3): 1201 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Anand, M. A. Kuskowski, T. S. Rector, V. G. Florea, R. D. Glazer, A. Hester, Y. T. Chiang, N. Aknay, A. P. Maggioni, C. Opasich, et al. Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure: Results From Val-HeFT Circulation, August 23, 2005; 112(8): 1121 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. van der Meer, E. Lipsic, R. H. Henning, K. Boddeus, J. van der Velden, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, and R. G. Schoemaker Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction J. Am. Coll. Cardiol., July 5, 2005; 46(1): 125 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. George, S. Patal, D. Wexler, A. Abashidze, H. Shmilovich, T. Barak, D. Sheps, and G. Keren Circulating Erythropoietin Levels and Prognosis in Patients With Congestive Heart Failure: Comparison With Neurohormonal and Inflammatory Markers Arch Intern Med, June 13, 2005; 165(11): 1304 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. M. Chaves, R. D. Semba, S. X. Leng, R. C. Woodman, L. Ferrucci, J. M. Guralnik, and L. P. Fried Impact of Anemia and Cardiovascular Disease on Frailty Status of Community-Dwelling Older Women: The Women's Health and Aging Studies I and II J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2005; 60(6): 729 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Namiuchi, Y. Kagaya, J. Ohta, N. Shiba, M. Sugi, M. Oikawa, H. Kunii, H. Yamao, N. Komatsu, M. Yui, et al. High Serum Erythropoietin Level Is Associated With Smaller Infarct Size in Patients With Acute Myocardial Infarction Who Undergo Successful Primary Percutaneous Coronary Intervention J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1406 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Felker, W. A. Gattis, K. F. Adams, and C. M. O'Connor Reply J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1550 - 1551. [Full Text] [PDF]
|
|
|
|
|
|
T. O. Cheng Is There an Optimal Hematocrit Value for Cardiac Patients? J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1549 - 1549. [Full Text]
|
|
|
|
|
|
S. Philipp, H. Ollmann, T. Schink, R. Dietz, F. C. Luft, and R. Willenbrock The impact of anaemia and kidney function in congestive heart failure and preserved systolic function Nephrol. Dial. Transplant., May 1, 2005; 20(5): 915 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Walsh, D. B. McClelland, R. J. Lee, M. Garrioch, C. R. Maciver, F. McArdle, S. L. Crofts, I. Mellor, and for the ATICS Study Group Prevalence of ischaemic heart disease at admission to intensive care and its influence on red cell transfusion thresholds: multicentre Scottish Study Br. J. Anaesth., April 1, 2005; 94(4): 445 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ishani, E. Weinhandl, Z. Zhao, D. T. Gilbertson, A. J. Collins, S. Yusuf, and C. A. Herzog Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction J. Am. Coll. Cardiol., February 1, 2005; 45(3): 391 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Maiese, F. Li, and Z. Z. Chong New Avenues of Exploration for Erythropoietin JAMA, January 5, 2005; 293(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Fried, C. Solomon, M. Shlipak, S. Seliger, C. Stehman-Breen, A. J. Bleyer, P. Chaves, C. Furberg, L. Kuller, and A. Newman Inflammatory and Prothrombotic Markers and the Progression of Renal Disease in Elderly Individuals J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3184 - 3191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Caiola and J. W. Cheng Use of Erythropoietin in Heart Failure Management Ann. Pharmacother., December 1, 2004; 38(12): 2145 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Guralnik, R. S. Eisenstaedt, L. Ferrucci, H. G. Klein, and R. C. Woodman Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia Blood, October 15, 2004; 104(8): 2263 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.M. Felker, K. F. Adams Jr, W. A. Gattis, and C. M. O'Connor Anemia as a risk factor and therapeutic target in heart failure J. Am. Coll. Cardiol., September 1, 2004; 44(5): 959 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A J S Coats Anaemia and heart failure Heart, September 1, 2004; 90(9): 977 - 979. [Full Text] [PDF]
|
|
|
|
|
|
P. van der Meer, A. A. Voors, E. Lipsic, T. D. J. Smilde, W. H. van Gilst, and D. J. van Veldhuisen Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure J. Am. Coll. Cardiol., July 7, 2004; 44(1): 63 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sharma, D. P Francis, B. Pitt, P. A Poole-Wilson, A. J.S Coats, and S. D Anker Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial Eur. Heart J., June 2, 2004; 25(12): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Z. Pantilat and A. E. Steimle Palliative Care for Patients With Heart Failure JAMA, May 26, 2004; 291(20): 2476 - 2482. [Abstract] |
